Tricida, Inc.

Informe acción OTCPK:TCDA.Q

Capitalización de mercado: US$580.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Tricida Dirección

Dirección controles de criterios 3/4

El CEO de Tricida es Gerrit Klaerner , nombrado en Aug 2013, tiene una permanencia de 9.83 años. compensación anual total es $4.68M, compuesta por 12.8% salario y 87.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.68% de las acciones de la empresa, por valor de $3.93. La antigüedad media del equipo directivo y de la junta directiva es de 4 años y 9.5 años, respectivamente.

Información clave

Gerrit Klaerner

Chief Executive Officer (CEO)

US$4.7m

Compensación total

Porcentaje del salario del CEO12.83%
Permanencia del CEO9.8yrs
Participación del CEO0.7%
Permanencia media de la dirección4yrs
Promedio de permanencia en la Junta Directiva9.5yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Oct 19

Tricida enters $125M debt facility

Tricida (NASDAQ:TCDA) gets into a debt facility of $125M with Hercules Capital, provider of customized debt financing for companies in the life sciences and technology-related markets. Of the $125M, $100M will be available for drawdown at Tricida’s option subject to the achievement of certain milestones. Under the terms of the debt facility, $25M will be available for drawdown until December 31, 2022, subject to the announcement of positive data from the VALOR-CKD trial.  An additional $25M will be available for drawdown until the earlier of ten business days following the filing of the NDA for veverimer and September 15, 2023. An additional $50M will be available for drawdown until the earlier of ten business days following the FDA approval of veverimer and February 15, 2024. The loans bear interest at a floating per annum interest rate equal to the greater of either 8.75% or the lesser of 8.75% plus the prime rate as reported in The Wall Street Journal minus 6.25% and 10.25%.
Seeking Alpha • Sep 21

Tricida: Important Binary Event Coming Up

Summary TCDA has a major binary event next month. Data from VALOR may turn out well given the logic behind early trial termination, prior data and so on. There could be some quick upside in the next 30 odd days. Tricida (TCDA) has been doing wonderfully lately, over the last 12 months, but it is down considerably from its PDUFA highs. That was from two years ago, when I used to cover the stock. I recall buying some TCDA, making good money, and then losing some money on the shares I held on to, because their lead asset veverimer was handed a CRL. The stock is up these days not because the CRL was resolved, but because of a number of other small and large things. Let's first discuss the CRL, though. Then we will see what has been responsible for the stock’s sudden buoyancy. Veverimer is targeting metabolic acidosis in CKD or chronic kidney disease patients. In an earlier trial, after 12 weeks of treatment, TRC101 or veverimer was able to increase blood bicarbonate level of at least 4 milliequivalents per liter (mEq/L) or achieved a blood bicarbonate level in the normal range of 22 to 29 mEq/L in 59.2% patients, compared with 22.5% of them in the placebo group (p< 0.0001). However, one of veverimer’s major problem is the standardly used therapy for this indication, which you can buy in a bottle from a grocery store for a few bucks. This is bicarbonate of soda, and while there have been no industry-sponsored trials for obvious reasons, it has long been used by doctors to treat metabolic acidosis. Its problem is that too much sodium content in the blood can cause heart diseases, which is where veverimer has a great deal of utility with its completely different mechanism of action. However, the FDA was not convinced, and it issued a CRL, asking for, among other things: Additional data regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate. Whether the demonstrated effect size would be reasonably likely to predict clinical benefit. I discussed all this in an earlier article from two years ago. A summary of the CRL from the company management was here: “According to the CRL, the FDA is seeking additional data beyond the TRCA-301 and TRCA-301E trials regarding the magnitude and durability of the treatment effect of veverimer on the surrogate marker of serum bicarbonate and the applicability of the treatment effect to the U.S. population. FDA also expressed concern as to whether the demonstrated effect size would be reasonably likely to predict clinical benefit,” Tricida said. This was an accelerated approval, and the company was already conducting VALOR-CKD at that time as a confirmatory trial. After the CRL, they said that interim data from this trial could be used to provide the data required by the FDA. This trial was supposed to enroll ~1500 patients and topline in 2023-24. In May, the company did an “administrative stop” to this trial after enrolling 1480 patients last year, and after 237 patients reached a primary endpoint event — end-stage renal disease, renal death, or greater than or equal to 40% reduction in eGFR or estimated glomerular filtration rate — in the renal outcomes study. This was done to conserve their cash reserve, which will be near depleted this quarter. Moreover, the FDA seems to have agreed that this may work. As Phil Nadeau at Cowen explained: Assuming a true hazard ratio ((HR)) of 0.70, the trial would be 78% powered at 250 events. Switching from power to observed HR, VALOR-CKD could be successful at 250 events if the observed HR is 0.78. There is only a modest increase to 0.79 observed HR should 300 events be in the final analysis. This calculation on the observed HR required for significance is based on 300 simulations on trial outcomes.
Artículo de análisis • Sep 14

Calculating The Intrinsic Value Of Tricida, Inc. (NASDAQ:TCDA)

Today we will run through one way of estimating the intrinsic value of Tricida, Inc. ( NASDAQ:TCDA ) by estimating the...
Artículo de análisis • Dec 14

Insider Buying: The Tricida, Inc. (NASDAQ:TCDA) CFO & Executive VP Just Bought 6.5% More Shares

Investors who take an interest in Tricida, Inc. ( NASDAQ:TCDA ) should definitely note that the CFO & Executive VP...

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Gerrit Klaerner en comparación con los beneficios de Tricida?
FechaCompensación totalSalarioIngresos de la empresa
Sep 30 2022n/an/a

-US$134m

Jun 30 2022n/an/a

-US$148m

Mar 31 2022n/an/a

-US$153m

Dec 31 2021US$5mUS$600k

-US$177m

Sep 30 2021n/an/a

-US$181m

Jun 30 2021n/an/a

-US$219m

Mar 31 2021n/an/a

-US$244m

Dec 31 2020US$9mUS$598k

-US$265m

Sep 30 2020n/an/a

-US$268m

Jun 30 2020n/an/a

-US$235m

Mar 31 2020n/an/a

-US$213m

Dec 31 2019US$10mUS$584k

-US$177m

Sep 30 2019n/an/a

-US$146m

Jun 30 2019n/an/a

-US$131m

Mar 31 2019n/an/a

-US$120m

Dec 31 2018US$1mUS$503k

-US$103m

Sep 30 2018n/an/a

-US$96m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$60m

Dec 31 2017US$821kUS$425k

-US$41m

Compensación vs. Mercado: La compensación total de Gerrit($USD4.68M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD655.15K).

Compensación vs. Ingresos: La compensación de Gerrit ha sido consistente con los resultados de la empresa en el último año.

CEO

Gerrit Klaerner (51 yo)

9.8yrs
Permanencia
US$4,676,490
Compensación

Dr. Gerrit Klaerner, Ph.D. Founded Tricida, Inc.and has been its Chief Executive Officer and President since August 2013 and has been its an Executive Director since July 2013. Dr. Klaerner was the Founder...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Gerrit Klaerner
Founder9.8yrsUS$4.68m0.68%
$ 3.9
Geoffrey Parker
COO, CFO & Executive VP6.2yrsUS$2.51m0.72%
$ 4.2
Robert McKague
Executive VP3.3yrsUS$2.43m0.031%
$ 0.2
Dawn Parsell
Executive Vice President of Clinical Development4.8yrsUS$2.77m0.0060%
$ 0.03
Annie Yoshiyama
VP of Finance & Chief Accounting Officer2.5yrssin datossin datos
Jackie Cossmon
Vice President of Investor Relations & Communicationsno datasin datossin datos
Edward Hejlek
Executive Vice President of Intellectual Property3.3yrsUS$2.10msin datos
4.0yrs
Permanencia media
58yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de TCDA.Q se considera experimentado (4 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Gerrit Klaerner
Founder9.9yrsUS$4.68m0.68%
$ 3.9
Kathryn Falberg
Independent Non-Employee Director5.1yrsUS$329.00k0.074%
$ 0.4
Klaus Veitinger
Independent Chairman of the Board9.3yrsUS$379.00k0.20%
$ 1.1
David Hirsch
Independent Non-Employee Director6.9yrsUS$326.50k0.019%
$ 0.1
Robert Alpern
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.7yrsUS$314.00ksin datos
John Fordtran
Member of Scientific & Clinical Advisory Boardno datasin datossin datos
David Bushinsky
Member of Scientific & Clinical Advisory Boardno datasin datossin datos
Craig Hawker
Member of Scientific & Clinical Advisory Boardno datasin datossin datos
Sandra Coufal
Independent Non-Employee Director and Member of Scientific & Clinical Advisory Board9.9yrsUS$316.50k0.15%
$ 0.9
Navdeep Tangri
Member of Scientific & Clinical Advisory Boardno datasin datossin datos
Thomas Hostetter
Member of Scientific & Clinical Advisory Boardno datasin datossin datos
Bertram Pitt
Member of Scientific and Clinical Advisory Boardno datasin datossin datos
9.5yrs
Permanencia media
60yo
Promedio de edad

Junta con experiencia: La junta directiva de TCDA.Q se considera experimentada (9.5 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2023/06/13 15:00
Precio de las acciones al final del día2023/06/13 00:00
Beneficios2022/09/30
Ingresos anuales2021/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Tricida, Inc. está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Dana FlandersGoldman Sachs
Jessica FyeJ.P. Morgan
Philip NadeauTD Cowen